Purui Benchmark Secures Over RMB 100 Million in New Financing to Advance Biology-AI Integration

Investment Circle (ID: pedaily2012) December 9th, by reporter, recently, Precision Scientific announcedCompleted a new round of financing exceeding 100 million yuan.This financingLed by Salubris, GUANGXI INVESTMENT GROUP, and ShenHong ZhongHeng Fund, with existing shareholders JinGu HuiFeng and JuYi Investment following up.This round of financing will focus on supporting Precision Scientific in its deep layout in the "biology + AI" field, and accelerating AI-driven drug research and development and innovative breakthroughs.

According to the official website, Precision Scientific is a novel platform company driven by "multi-omics + data mining," focusing on differentiated R&D strategies for innovative drugs. With advanced multi-omics technology, bioinformatics, and AI algorithms at its core, the company leverages its independently developed AI-driven massive multi-omics data mining system, AIBERT®, to provide pharmaceutical enterprises and biotech companies with world-leading innovative services in drug mechanism research, biomarker development, biomarker-based and precision medicine-oriented clinical differentiation strategies for drug R&D, clinical statistics, central laboratories, and co-development of drug companion diagnostics. It has established deep collaborations with multiple leading domestic and international pharmaceutical enterprises and biotech companies, facilitating the R&D and approval of various new drugs. Meanwhile, on the clinical side, the company works closely with partner pharmaceutical firms and doctors to provide patients with advanced and precise testing services, supporting the clinical practice of precision medication.

Precision Scientific has long been dedicated to the "biology + AI" field, continuously exploring applications that combine biology with AI and computational methods. The company has developed AIBERT, an AI-driven system for mining massive multi-omics data aimed at new drug research and development. By analyzing multi-omics data, AIBERT provides decision support for differentiated new drug development strategies, including innovative target discovery/evaluation, indication selection, novel biomarker discovery, resistance mechanism research, and combination therapy exploration. The company also addresses unmet clinical testing needs by analyzing omics data to discover multiple innovative disease biomarkers. Based on these novel biomarkers, Precision Scientific collaborates with several academicians and clinical experts to develop world-leading diagnostic products (focusing on gynecological oncology).

Duan Feng, General Manager of the Investment Department of Salubris, said:This transaction will help Salubris further improve R&D efficiency, find new pathways to address unmet clinical needs, and accelerate the development of cardio-renal metabolism drugs. It is expected to enhance the company's overall strength in new drug development and provide new exploration for its innovative drug research, aligning with industry trends and the company’s long-term strategy.